Ethical Conflict in Providing Informed Consent for Clinical Trials: A Problematic Example from the Gynecologic Cancer Research Community

Oncologist

Volumn 9, Issue 1, 2004, Pages 3-7

  Markman, Maurie ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Informed consent in clinical research; Ovarian cancer; Paclitaxel; Randomized trials

Indexed keywords

PACLITAXEL; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER STAGING; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ETHICS; GYNECOLOGIC CANCER; HUMAN; INFORMED CONSENT; MAINTENANCE THERAPY; OVARY CANCER; PATIENT INFORMATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS, PHASE III; DISEASE PROGRESSION; FEMALE; HUMANS; INFORMED CONSENT; MORAL OBLIGATIONS; OVARIAN NEOPLASMS; PACLITAXEL; PATIENT EDUCATION; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SOCIAL RESPONSIBILITY; SURVIVAL ANALYSIS;

EID: 1642457366     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-1-3     Document Type: Review

References (10)

1. Beecher HK. Ethics and clinical research. N Engl J Med 1966;274:1354-1360.
2. Levinsky NG. Nonfinancial conflicts of interest in research. N Engl J Med 2002;347:759-761.
3. Markman M, Liu PY, Wilczynski S et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003;21:2460-2465.
4. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1-6.
5. Markman M, Bookman MA. Second-line treatment of ovarian cancer. The Oncologist 2000;5:26-35.
6. Markman M, Hakes T, Barakat R et al. Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. J Clin Oncol 1996;14:796-799.
7. Schafer A. The ethics of the randomized clinical trial. N Engl J Med 1982;307:719-724.
8. Emanuel EJ, Patterson WB. Ethics of randomized clinical trials. J Clin Oncol 1998;16:365-366; discussion 366-371.
9. Smith MA, Ungerleider RS, Korn EL et al. Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. J Clin Oncol 1997;15:2736-2743.
10. Department of Health and Human Services. Regulations for the Protection of Human Subjects (45 CFR 46), Section 46.116: General Requirements for Informed Consent. Code of Federal Regulations: Department of Health and Human Services.